StockNews.AI
VRTX
StockNews.AI
204 days

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

1. Vertex Pharmaceuticals will report Q4 2024 results on February 10, 2025. 2. Conference call scheduled at 4:30 p.m. ET for earnings discussion. 3. Vertex develops transformative medicines for serious diseases like cystic fibrosis. 4. Company has ongoing research in various serious diseases beyond cystic fibrosis. 5. Vertex consistently ranks as a top employer in biotech industry.

Earnings
+0.97%Current Return
VS
-0.75%S&P 500
$439.6201/27 07:33 AM EDTEvent Start
$443.8901/28 02:10 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements can create volatility, but no significant trend is indicated.

How important is it?

Earnings results are crucial for assessing company performance; however, substantial developments are not highlighted.

Why Short Term?

Q4 results may influence stock price temporarily; long-term trends depend on pipeline success.

Related Companies

VRTX
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X. (VRTX-WEB)

Related News